CD19 and plasma cell myeloma: Even though CD19 CAR T-cells demonstrated remarkable results in treating certain B-cell malignancies, it was unable to effectively eliminate myeloma cells due to the lower expression of CD19 on the surface of myeloma cells [100, 101].